trending Market Intelligence /marketintelligence/en/news-insights/trending/ksljuo2qd8mc_fovyv-jfq2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

UK regulator grants early patient access to Akcea's rare disease drug

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

UK regulator grants early patient access to Akcea's rare disease drug

Akcea Therapeutics Inc. said a U.K. regulator granted early patient access to its drug volanesorsen for familial chylomicronemia syndrome, a rare genetic disease.

The medicine received a positive scientific opinion from the U.K's Medicines and Healthcare Products Regulatory Agency for treating familial chylomicronemia syndrome.

The U.K. regulator granted the positive opinion through the early access to medicines scheme, a program designed to give patients with life threatening or seriously debilitating conditions access to treatments that have not yet received marketing authorization from the European Commission.

Familial chylomicronemia syndrome is a rare genetic condition that prevents the body from breaking down fats, causing abdominal pain with a high risk of recurrent, potentially fatal, acute pancreatitis.

The positive opinion was granted to Akcea unit Akcea Therapeutics U.K. Ltd.

Akcea Therapeutics, a unit of Ionis Pharmaceuticals Inc., developed volanesorsen using Ionis' proprietary antisense technology for treating rare metabolic disorders. Akcea recently acquired the rights to Ionis' inotersen and AKCEA-TTR-L drugs indicated to treat forms of transthyretin amyloidosis, a progressive, sometimes fatal, genetic disease.